Skip to main content
OpenTrials

Clinical trial condition

Neoplasms by Site

Explore clinical trials studying Neoplasms by Site. Study availability and eligibility vary by location and protocol.

50,459 public trials 10,713 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms by Site trial results

Recruiting

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

NCT07543757

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Idaho Urologic Institute Meridian, Idaho, United States
  • Graves Gilbert Clinic Bowling Green, Kentucky, United States
  • Chesapeake Urology Associates Hanover, Maryland, United States
  • Chesapeake Urology Associates Towson, Maryland, United States
View Trial Details
Recruiting

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

NCT01109394

Conditions
Endocrine Tumors, Eye Diseases, Eye Diseases, Hereditary, +27 more
Locations
  • Children's National Medical Center Washington D.C., District of Columbia, United States
  • Children's Hospital of Orange County (CHOC Children's) Orange, Florida, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • Tisch Cancer Institute, Mount Sinai Medical Center New York, United States
View Trial Details
Recruiting

Fruquintinib in Patients With Metastatic Colorectal Cancer

NCT06787105

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
Locations
  • Onkologische Schwerpunktpraxis Hanover, Lower Saxony, Germany
  • Hämatologikum Biberach Biberach, Baden-Wurttemberg, Germany
  • Praxis für interdisziplinäre Onkologie & Hämatologie Freiburg im Breisgau, Baden-Wurttemberg, Germany
  • Onkologische Schwerpunktpraxis Heidelberg, Baden-Wurttemberg, Germany
View all 42 locations
View Trial Details
Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Mayo Clinic Hospital - Phoenix /ID# 272971 Phoenix, Arizona, United States
  • Providence - St. Jude Medical Center /ID# 271414 Fullerton, California, United States
  • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450 Oxnard, California, United States
  • UCLA - Santa Monica /ID# 271690 Santa Monica, California, United States
View all 119 locations
View Trial Details
Recruiting

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

NCT05372614

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +15 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care Irvine, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • City of Hope Antelope Valley Lancaster, California, United States
View all 18 locations
View Trial Details
Recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852

Conditions
Breast Diseases, Breast Neoplasms, Metastatic Breast Cancer, +4 more
Locations
  • Ironwood Cancer & Research Centers Chandler, Arizona, United States
  • Ironwood Cancer & Research Centers Gilbert, Arizona, United States
  • Ironwood Cancer & Research Centers Glendale, Arizona, United States
  • Ironwood Cancer & Research Centers Goodyear, Arizona, United States
View all 73 locations
View Trial Details
Recruiting

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

NCT07287917

Conditions
Breast Diseases, Breast Neoplasms, HER2-low Hormone Receptor Positive Breast Cancer, +13 more
Locations
  • University of Arizona Tucson, Arizona, United States
  • START Los Angeles Los Angeles, California, United States
  • Skin Cancer Institute Englewood, Colorado, United States
  • Wayne State University - Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
View all 20 locations
View Trial Details

Related conditions